The phase III trial REACH‐2 studied ramucirumab in patients with advanced HCC and AFP greater than 400 and showed significant improvement in OS as compared to placebo (HR 0.71; 95% CI, 0.53‐0.94; P = 0.0199).15 Cabozantinib is an oral multikinase inhibitor with activity against MET, AXL, and VEGF receptors 1‐3. Here, AFP is linked to hepatocellular carcinoma.